Pancreatic
BGB-11417-304
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Acalabrutinib in Patient with Previously Untreated Chronic Lymphocytic Leukaemia
Trial overview
Clinical Area
Haematology
Disease
Leukaemia
Disease site
Malignant Haematology
Study Phase
III
Trial Identifiers
Registration number: NCT07277231
GenesisCare Location(s)
Principal Investigator(s)